文献速递泌尿生殖MRUS

多中心随机试验评估MRI与影像引导活检对疑似前列腺癌的诊断价值:MULTIPROS研究

Multicenter Randomized Trial Assessing MRI and Image-guided Biopsy for Suspected Prostate Cancer: The MULTIPROS Study.
PubMed 文献 · Radiology · 2023-01-01

这项前瞻性随机对照试验纳入582例疑似前列腺癌男性,评估活检前多参数MRI以根治性前列腺切除标本为参考标准诊断临床显著前列腺癌的准确性,并比较系统随机活检与超声MRI融合靶向活检联合系统活检的检出率。413例PI-RADS≥3者随机分组,联合活检组临床显著前列腺癌检出率更高(调整OR 1.79,95%CI 1.14-2.79,P=0.01)。

要点

  • 活检前多参数MRI诊断临床显著前列腺癌敏感度72%(95%CI 65-78),特异度71%(91/128)。
  • MRI与超声融合靶向活检联合系统活检较单用系统活检检出更多临床显著病灶(调整OR 1.79,P=0.01)。
  • 多参数MRI正确识别89例根治标本中182个临床显著癌灶的131个,阳性预测值78%、阴性预测值64%。

核心结论

  • 活检前多参数MRI能准确显示临床显著前列腺癌;超声与MRI融合靶向活检联合系统活检较单用系统活检有助于检出更多临床显著病灶。

研究设计与样本

  • 前瞻性随机对照试验,纳入大学医院疑似前列腺癌男性,2015年1月至2020年8月招募,582例符合多参数MRI条件,413例PI-RADS≥3者按1:1随机分为系统随机活检对照组(206/413,49.9%)与融合靶向联合系统活检干预组(207/413,50.1%),其中89例(21.5%,89/413)接受根治性前列腺切除组织学切片作为参考标准;临床试验注册号NCT02745496。

诊断标准与关键数值

  • 以根治性前列腺切除标本为参考标准,多参数MRI识别临床显著前列腺癌的敏感度为72%(95%CI 65-78),特异度71%(91/128),阳性预测值78%(131/168),阴性预测值64%(91/142)。

临床应用与阅片要点

  • 对PI-RADS≥3的疑似前列腺癌患者,采用超声与MRI融合靶向活检联合系统随机活检较单用系统随机活检可检出更多临床显著前列腺癌(调整OR 1.79,95%CI 1.14-2.79,P=0.01)。

局限性

  • 原文在背景中指出前列腺癌最佳诊断路径仍在演变,需要进一步在随机对照试验中评估。
  • 原文仅89例(21.5%,89/413)接受根治性前列腺切除组织学参考标准,为总随机人群的子集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The optimal diagnostic pathway for prostate cancer (PCa) is evolving, requiring further evaluation in a randomized controlled trial. Purpose To assess the diagnostic accuracy of prebiopsy multiparametric MRI in the identification of clinically significant PCa (csPCa) using radical prostatectomy (RP) specimens as the reference standard, and to test the diagnostic accuracy of combined US and MRI fusion-targeted biopsy with systematic biopsies. Materials and Methods In a prospective randomized controlled trial including university hospitals, men with suspected PCa were recruited between January 2015 and August 2020 to assess the diagnostic accuracy of multiparametric MRI before biopsy in detection of csPCa at biopsy and RP histopathologic structure (primary outcome). Men with lesions suspicious for cancer (Prostate Imaging and Reporting Data System [PI-RADS] ≥3) at multiparametric MRI were first randomized to either systematic random prostate biopsies alone (control group) or US and MRI fusion-targeted biopsies with systematic random prostate biopsies (intervention group) at a one-to-one ratio to compare the diagnostic accuracy of systematic random versus combined fusion with systematic random biopsies (secondary outcome). A subset of recruited participants (n = 89) underwent RP and histologic sectioning. Results There were 582 participants who were eligible to undergo multiparametric MRI (mean age, 65 years ± 6 [SD]). In total, 413 had a PI-RADS score of at least 3 and were randomized into either the intervention group (207 of 413; 50.1%) or control group (206 of 413; 49.9%). The csPCa detection rate in the intervention group was higher, with an adjusted odds ratio of 1.79 (95% CI: 1.14, 2.79; P = .01). A subgroup of 89 men underwent RP (21.5%; 89 of 413). Multiparametric MRI helped correctly identify 131 of 182 csPCa foci in 89 men (sensitivity, 72%; 95% CI: 65, 78). The specificity, positive predictive value, and negative predictive value were 71% (91 of 128), 78% (131 of 168), and 64% (91 of 142), respectively. Conclusion Prebiopsy multiparametric MRI was accurate in the depiction of clinically significant PCa. Combining US and MRI fusion-targeted biopsies with systematic biopsies helped detect more clinically significant lesions than did systematic biopsies alone. Clinical trial registration no. NCT02745496 © RSNA, 2023 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Wei C, Szewczyk-Bieda M, Bates AS, et al. Multicenter Randomized Trial Assessing MRI and Image-guided Biopsy for Suspected Prostate Cancer: The MULTIPROS Study. Radiology. 2023. PMID: 37489992. doi:10.1148/radiol.221428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。